Generate Biomedicines (NASDAQ:GENB) Stock Crosses Below 200-Day Moving Average – Time to Sell?

Shares of Generate Biomedicines Inc (NASDAQ:GENB) passed below its 200-day moving average during trading on Thursday. The stock has a 200-day moving average of $14.14 and traded as low as $12.46. Generate Biomedicines shares last traded at $12.57, with a volume of 1,298,162 shares.

Wall Street Analyst Weigh In

GENB has been the subject of several recent research reports. Weiss Ratings raised Generate Biomedicines from a “sell (d)” rating to a “sell (d+)” rating in a report on Friday, September 25th. Wall Street Zen lowered Generate Biomedicines from a “hold” rating to a “sell” rating in a report on Saturday, October 17th. Finally, HC Wainwright restated a “buy” rating on shares of Generate Biomedicines in a research report on Friday, October 30th. Six research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $26.40.

Generate Biomedicines Price Performance

The firm has a market cap of $1.68 billion and a P/E ratio of -8.21. The stock’s 50 day moving average is $14.61 and its two-hundred day moving average is $14.14.

Generate Biomedicines (NASDAQ:GENB) last announced its quarterly earnings results on Thursday, August 6th. The company reported ($0.52) EPS for the quarter, missing analysts’ consensus estimates of ($0.48) by ($0.04). The business had revenue of $6.31 million for the quarter. As a group, research analysts forecast that Generate Biomedicines Inc will post -2.29 EPS for the current fiscal year.

Hedge Funds Weigh In On Generate Biomedicines

Several hedge funds and other institutional investors have recently modified their holdings of the stock. Magnus Financial Group LLC boosted its stake in Generate Biomedicines by 39.4% in the 3rd quarter. Magnus Financial Group LLC now owns 21,750 shares of the company’s stock valued at $327,000 after buying an additional 6,150 shares in the last quarter. Susquehanna International Group LLP bought a new position in shares of Generate Biomedicines during the second quarter valued at $196,000. AXQ Capital LP bought a new position in shares of Generate Biomedicines during the second quarter valued at $218,000. Summa Corp. acquired a new stake in shares of Generate Biomedicines in the 3rd quarter valued at $250,000. Finally, Squarepoint Ops LLC acquired a new stake in shares of Generate Biomedicines in the 2nd quarter valued at $530,000.

Generate Biomedicines Company Profile

Generate Biomedicines is a biotechnology company that uses generative artificial intelligence, machine learning and protein engineering to design novel protein-based medicines. Its platform is intended to identify and develop therapeutic proteins with desired biological properties, potentially shortening the time required to discover new drug candidates.

The company’s research activities focus on applying computational biology and laboratory experimentation to create medicines for a range of diseases, including conditions in immunology, inflammation, oncology and other areas of significant unmet medical need.